<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mafenide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mafenide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mafenide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11204" href="/d/html/11204.html" rel="external">see "Mafenide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12567" href="/d/html/12567.html" rel="external">see "Mafenide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190673"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sulfamylon</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190686"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F190674"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b818ec7-0784-430c-b38c-ba8aa5299df2">Burn treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Burn treatment:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Refer to institutional policies and procedures; application specifics may vary.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream: Apply once or twice daily with a sterile-gloved hand, to a thickness of approximately <sup>1</sup>/<sub>16</sub> inch, or enough to prevent burn dressing adhesion to the wound (thicker application is not needed). The burned area should be covered with cream at all times. Continue treatment until healing is progressing well or the burn site is ready for grafting (Cancio 2017; ISBI 2016; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for solution (2.5% or 5%): Wet a burn dressing (eg, gauze) with mafenide topical solution and cover graft area. Keep dressing damp/moist using an irrigation syringe or irrigation tubing every 4 to 12 hours (or as necessary). Avoid maceration through over-wetting or avoid adhesion to wound (if dressing is directly in contact with burn) through over-drying. Continue treatment until healing is progressing well or the burn site is ready for grafting (Afshari 2017; Cancio 2017; Ibrahim 2014; ISBI 2016; manufacturer’s labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990094"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution, accumulation of parent drug and metabolite may enhance carbonic anhydrase inhibition.</p></div>
<div class="block doha drugH1Div" id="F50987378"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F4302935"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Acidosis: When acidosis becomes difficult to control, discontinuing treatment for 24 to 48 hours may aid in restoring acid-base balance</p></div>
<div class="block doe drugH1Div" id="F190675"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F190681"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12567" href="/d/html/12567.html" rel="external">see "Mafenide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea7970bc-7ae0-4b3b-963a-54fafff75969">Burns</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Burns:</b> Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Infants, Children, and Adolescents: Apply once or twice daily with a sterile-gloved hand; apply to a thickness of approximately <sup>1</sup>/<sub>16</sub> inch; the burned area should be covered with cream at all times.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution (5%): Infants ≥3 months, Children, and Adolescents: Cover graft area with 1 layer of fine mesh gauze. Wet an 8-ply burn dressing with mafenide solution and cover graft area. Keep dressing wet using syringe or irrigation tubing every 4 hours (or as necessary), or by moistening dressing every 6 to 8 hours (or as necessary). Irrigation dressing should be secured with bolster dressing and wrapped as appropriate. May leave dressings in place for up to 5 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129044"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution, accumulation of parent drug and metabolite may enhance carbonic anhydrase inhibition.</p></div>
<div class="block dohp drugH1Div" id="F51129045"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F190653"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Edema, facial edema</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Erythema, maceration, pruritus, rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hyperchloremia, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (following accidental ingestion)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic: Bleeding, bone marrow suppression, DIC, eosinophilia, hemolytic anemia, porphyria</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Blisters, burning sensation, excoriation, pain</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, hyperventilation, pCO<sub>2</sub> decreased, tachypnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Hypersensitivity</p></div>
<div class="block coi drugH1Div" id="F190665"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to mafenide or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F190650"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acid-base imbalance: Mafenide and its metabolite inhibit carbonic anhydrase; metabolic acidosis may occur. Symptoms may include compensatory hyperventilation; risk is increased in patients with impaired renal function. Some patients experience masked hyperventilation and respiratory alkalosis; etiology is unknown. Monitor acid-base balance, especially in patients with extensive second-degree or partial-thickness burns and in patients with pulmonary or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use caution in patients with G6PD deficiency; hemolytic anemia with DIC (including fatalities) has been reported with use, presumably related to G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in burn patients with acute renal impairment; accumulation of parent drug and metabolite may enhance carbonic anhydrase inhibition and increase risk of metabolic acidosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Some dosage forms contain sulfites which may cause allergic-type reactions (including anaphylaxis) as well as life-threatening or less severe asthmatic episodes in certain individuals; consider discontinuation of therapy if allergic reactions occur.</p></div>
<div class="block foc drugH1Div" id="F190660"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as acetate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulfamylon: 85 mg/g (56.7 g, 453.6 g) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulfamylon: 85 mg/g (56.7 g [DSC], 113.4 g [DSC], 453.6 g [DSC]) [contains methylparaben, propylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, External, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulfamylon: 50 g (1 ea, 5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 g (1 ea, 5 ea)</p></div>
<div class="block geq drugH1Div" id="F190646"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323349"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Sulfamylon External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">85 mg/g (per gram): $1.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Mafenide Acetate External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $160.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Sulfamylon External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $122.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F4303178"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> For external use only.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream: Keep burn area covered with cream at all times. Dressings usually are not required; however, if necessary, only a thin layer of dressings should be used. Apply to clean debrided area with a sterile gloved hand. If possible, patient should bathe daily to aid debridement (eg, whirlpool bath, shower, or bathed in bed).</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for solution (2.5% or 5%): Cover graft area with 1 layer of fine mesh gauze. Wet dressing (eg, gauze) with the mafenide topical solution and cover graft area. Keep dressing damp/moist using an irrigation syringe or irrigation tubing. Irrigation tubing should be placed over burn dressing in contact with the wound; use an additional dressing to cover. Irrigation dressing should be secured with bolster dressing and wrapped as appropriate. Avoid maceration through over-wetting or avoid adhesion to wound (if dressing is directly in contact with burn) through over-drying (Afshari 2017; Ibrahim 2014; ISBI 2016; manufacturer’s labeling).</p></div>
<div class="block admp drugH1Div" id="F52613202"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For topical use only.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Apply to cleansed, debrided, burned area with a sterile-gloved hand. Keep burn area covered with cream at all times.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Cover affected area with gauze and the dressing wetted with mafenide solution; wound dressing may be left undisturbed for up to 5 days.</p></div>
<div class="block use drugH1Div" id="F190661"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Burn treatment: </b>Adjunctive therapy of patients with second- and third-degree burns (cream); adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds (powder for solution)</p></div>
<div class="block cyt drugH1Div" id="F13299625"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F190654"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53578100"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The manufacturer does not recommend use of the cream in women of childbearing potential unless the burn area covers &gt;20% of the total body surface.</p></div>
<div class="block pri drugH1Div" id="F4302933"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The manufacturer does not recommend use of the cream unless the benefits of treatment outweigh possible risks to the fetus.</p></div>
<div class="block brc drugH1Div" id="F20616121"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if mafenide is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F190658"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Metabolic acidosis; rash; local wound infection; wound healing.</p></div>
<div class="block pha drugH1Div" id="F190649"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a sulfonamide, mafenide interferes with bacterial folic acid synthesis through competitive inhibition of para-aminobenzoic acid. Spectrum of activity encompasses both gram positive and negative organisms, including <i>Pseudomonas</i> and some anaerobes. </p></div>
<div class="block phk drugH1Div" id="F190664"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Diffuses through devascularized areas and is rapidly absorbed from burned surface </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: To para-carboxybenzene sulfonamide; mafenide and metabolite are carbonic anhydrase inhibitors </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Cream 11%: 2 to 4 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Burn tissue: Cream 11%: 2 hours, Solution 5%: 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as metabolites) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038668"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sulfamylon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Napaltan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sulfamylon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mapec | Mefede | Sulfamylon | Sulfaron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sulfamylon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sulfamylon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Pyrotin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27606553">
<a name="27606553"></a>Afshari A, Nguyen L, Kahn SA, Summitt B. 2.5% Mafenide acetate: a cost-effective alternative to the 5% solution for burn wounds. <i>J Burn Care Res</i>. 2017;38(1):e42-e47. doi:10.1097/BCR.0000000000000425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mafenide-drug-information/abstract-text/27606553/pubmed" id="27606553" target="_blank">27606553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27355660">
<a name="27355660"></a>Cancio LC, Barillo DJ, Kearns RD, et al. Guidelines for burn care under austere conditions: surgical and nonsurgical wound management. <i>J Burn Care Res.</i> 2017;38(4):203-214. doi:10.1097/BCR.0000000000000368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mafenide-drug-information/abstract-text/27355660/pubmed" id="27355660" target="_blank">27355660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24043238">
<a name="24043238"></a>Ibrahim A, Fagan S, Keaney T, et al. A simple cost-saving measure: 2.5% mafenide acetate solution. <i>J Burn Care Res.</i> 2014;35(4):349-353. doi:10.1097/BCR.0b013e3182a22715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mafenide-drug-information/abstract-text/24043238/pubmed" id="24043238" target="_blank">24043238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27542292">
<a name="27542292"></a>International Society for Burn Injury (ISBI). ISBI Practice Guidelines Committee; Steering Subcommittee; Advisory Subcommittee. ISBI practice guidelines for burn care. <i>Burns</i>. 2016;42(5):953-1021. doi:10.1016/j.burns.2016.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mafenide-drug-information/abstract-text/27542292/pubmed" id="27542292" target="_blank">27542292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  Sulfamylon (mafenide) cream [prescribing information]. East Brunswick, NJ: Rising Pharma Holdings Inc; August 2020.</div>
</li>
<li>
<div class="reference">
                  Sulfamylon (mafenide) powder for solution [prescribing information]. Rockford, IL: Mylan Institutional Inc; June 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9579 Version 170.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
